Pioglitazone counteracts the tumor necrosis factor-α inhibition of follicle-stimulating hormone-induced follicular development and estradiol production in an in vitro mouse preantral follicle culture system

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Hara, Shuichiro ^a   Takahashi, Toshifumi ^a   Amita, Mitsuyoshi ^a   Matsuo, Koki ^a   Igarashi, Hideki ^a   Kurachi, Hirohisa ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Follicle culture; Pioglitazone; Polycystic ovary syndrome; PPAR ; TNF

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; COMPETITIVE INHIBITION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; FEMALE; IN VITRO STUDY; INSULIN RESISTANCE; MOUSE; NONHUMAN; OVARY FOLLICLE; OVARY FOLLICLE CELL; OVARY FOLLICLE DEVELOPMENT; OVARY POLYCYSTIC DISEASE; OVULATION; PRIORITY JOURNAL; STEROIDOGENESIS;

EID: 84884696601     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-69     Document Type: Article

References (47)

1. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF, J Clin Endocrinol Metab 2000 85 2434 2438 10.1210/jc.85.7.2434 10902790 (Pubitemid 32269197)
2. ACOG practice bulletin no. 108: polycystic ovary syndrome. American College of Obstetricians and Gynecologists, Obstet Gynecol 2009 114 936 949 10.1097/AOG.0b013e3181bd12cb 19888063
3. Metformin for the treatment of the polycystic ovary syndrome. Nestler JE, N Engl J Med 2008 358 47 54 10.1056/NEJMct0707092 18172174
4. Minireview: up-date management of non responder to clomiphene citrate in polycystic ovary syndrome. Amin M, Abdel-Kareem O, Takekida S, Moriyama T, Abd el-Aal G, Maruo T, Kobe J Med Sci 2003 49 59 73 14676484 (Pubitemid 38477600)
5. A mechanism for the suppression of estrogen production in polycystic ovary syndrome. Agarwal SK, Judd HL, Magoffin DA, J Clin Endocrinol Metab 1996 81 3686 3691 10.1210/jc.81.10.3686 8855823 (Pubitemid 26339938)
6. Aromatase mRNA expression in individual follicles from polycystic ovaries. Jakimiuk AJ, Weitsman SR, Brzechffa PR, Magoffin DA, Mol Hum Reprod 1998 4 1 8 10.1093/molehr/4.1.1 9510005 (Pubitemid 28109154)
7. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P, Metabolism 1999 48 437 441 10.1016/S0026- 0495(99)90100-2 10206434 (Pubitemid 29174220)
8. Association between circulating tumor necrosis factor-alpha, interleukin-6, and insulin resistance in normal-weight women with polycystic ovary syndrome. Tarkun I, Cetinarslan B, Turemen E, Canturk Z, Biyikli M, Metab Syndr Relat Disord 2006 4 122 128 10.1089/met.2006.4.122 18370758 (Pubitemid 44122702)
9. Tumor necrosis factor alpha enhances oocyte/follicle apoptosis in the neonatal rat ovary. Morrison LJ, Marcinkiewicz JL, Biol Reprod 2002 66 450 457 10.1095/biolreprod66.2.450 11804962 (Pubitemid 34101844)
10. Apoptosis in the ovary: molecular mechanisms. Hussein MR, Hum Reprod Update 2005 11 162 177 15705959
11. Steroidogenesis, proliferation and apoptosis in bovine granulosa cells: role of tumour necrosis factor-alpha and its possible signalling mechanisms. Basini G, Mainardi GL, Bussolati S, Tamanini C, Reprod Fertil Dev 2002 14 141 150 10.1071/RD01049 12219935
12. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. DeUgarte CM, Bartolucci AA, Azziz R, Fertil Steril 2005 83 1454 1460 10.1016/j.fertnstert.2004.11.070 15866584 (Pubitemid 40615820)
13. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Diamanti-Kandarakis E, Dunaif A, Endocr Rev 2012 33 981 1030 10.1210/er.2011-1034 23065822
14. Use of metformin in polycystic ovary syndrome. Mathur R, Alexander CJ, Yano J, Trivax B, Azziz R, Am J Obstet Gynecol 2008 199 596 609 10.1016/j.ajog.2008.09.010 19084097
15. Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. Kim CH, Jeon GH, Kim SR, Kim SH, Chae HD, Kang BM, Fertil Steril 2010 94 236 241 10.1016/j.fertnstert.2009.02.029 19324344
16. Insulin-lowering drugs in polycystic ovary syndrome. Iuorno MJ, Nestler JE, Obstet Gynecol Clin North Am 2001 28 153 164 10.1016/S0889-8545(05)70191-1 11293000 (Pubitemid 32242546)
17. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH, Cochrane Database Syst Rev 2012 5 D003053 22592687
18. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Cariou B, Charbonnel B, Staels B, Trends Endocrinol Metab 2012 23 205 215 10.1016/j.tem.2012.03.001 22513163
19. Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials. Du Q, Yang S, Wang YJ, Wu B, Zhao YY, Fan B, Adv Ther 2012 29 763 774 10.1007/s12325-012-0044-6 22932791
20. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Koo YA, Shin SY, Yoon BK, Choi D, Gynecol Endocrinol 2007 23 461 467 10.1080/09513590701492689 17852414 (Pubitemid 47575050)
21. Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Ota H, Goto T, Yoshioka T, Ohyama N, Fertil Steril 2008 90 709 713 10.1016/j.fertnstert.2007.01.117 18423625
22. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. Seto-Young D, Paliou M, Schlosser J, Avtanski D, Park A, Patel P, Holcomb K, Chang P, Poretsky L, J Clin Endocrinol Metab 2005 90 6099 6105 10.1210/jc.2005-0469 16131582 (Pubitemid 41606531)
23. Bezafibrate restores the inhibition of FSH-induced follicular development and steroidogenesis by tumor necrosis factor-alpha through peroxisome proliferator-activated receptor-gamma pathway in an in vitro mouse preantral follicle culture. Hara S, Takahashi T, Amita M, Igarashi H, Tsutsumi S, Kurachi H, Biol Reprod 2011 85 895 906 10.1095/biolreprod.111.090738 21734263
24. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S, Arch Intern Med 2006 166 737 741 10.1001/archinte.166.7.737 16606809
25. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S, Circulation 2004 109 2197 2202 10.1161/01.CIR.0000126824.12785.B6 15123532 (Pubitemid 38656105)
26. Functional AR signaling is evident in an in vitro mouse follicle culture bioassay that encompasses most stages of folliculogenesis. Lenie S, Smitz J, Biol Reprod 2009 80 685 695 10.1095/biolreprod.107.067280 19074005
27. Differences in collagen expression in cumulus cells after exposure to highly purified menotropin or recombinant follicle-stimulating hormone in a mouse follicle culture model. Adriaenssens T, Mazoyer C, Segers I, Wathlet S, Smitz J, Biol Reprod 2009 80 1015 1025 10.1095/biolreprod.107.067462 19164180
28. A reproducible two-step culture system for isolated primary mouse ovarian follicles as single functional units. Lenie S, Cortvrindt R, Adriaenssens T, Smitz J, Biol Reprod 2004 71 1730 1738 10.1095/biolreprod.104.028415 15240420 (Pubitemid 39403272)
29. Differential FSH exposure in preantral follicle culture has marked effects on folliculogenesis and oocyte developmental competence. Adriaens I, Cortvrindt R, Smitz J, Hum Reprod 2004 19 398 408 10.1093/humrep/deh074 14747188 (Pubitemid 38220014)
30. Contenders in FasL/TNF death signaling. Cleveland JL, Ihle JN, Cell 1995 81 479 482 10.1016/0092-8674(95)90068-3 7758103
31. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Amato G, Conte M, Mazziotti G, Lalli E, Vitolo G, Tucker AT, Bellastella A, Carella C, Izzo A, Obstet Gynecol 2003 101 1177 1182 10.1016/S0029-7844(03)00233-3 12798522 (Pubitemid 36694341)
32. Serum asymmetric dimethylarginine, apelin, and tumor necrosis factor-alpha levels in non-obese women with polycystic ovary syndrome. Choi YS, Yang HI, Cho S, Jung JA, Jeon YE, Kim HY, Seo SK, Lee BS, Steroids 2012 77 1352 1358 10.1016/j.steroids.2012.08.005 22944040
33. Factors influencing the rate of preantral and antral growth of mouse ovarian follicles in vitro. Nayudu PL, Osborn SM, J Reprod Fertil 1992 95 349 362 10.1530/jrf.0.0950349 1517993
34. In vitro culture of ovarian follicles. Hartshorne GM, Rev Reprod 1997 2 94 104 10.1530/ror.0.0020094 9414471 (Pubitemid 27271667)
35. Follicle culture in reproductive toxicology: a tool for in-vitro testing of ovarian function? Cortvrindt RG, Smitz JE, Hum Reprod Update 2002 8 243 254 10.1093/humupd/8.3.243 12078835 (Pubitemid 34618943)
36. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Gonzalez F, Steroids 2012 77 300 305 10.1016/j.steroids.2011.12.003 22178787
37. Tumor necrosis factor alpha inhibition of follicle-stimulating hormone-induced granulosa cell estradiol secretion in the human does not involve reduction of cAMP secretion but inhibition at post-cAMP site(s). Montgomery Rice V, Limback SD, Roby KF, Terranova PF, Endocrine 1999 10 19 23 10.1385/ENDO:10:1:19 10403567 (Pubitemid 29203580)
38. The expression of tumor necrosis factor-alpha, its receptors and steroidogenic acute regulatory protein during corpus luteum regression. Abdo M, Hisheh S, Arfuso F, Dharmarajan A, Reprod Biol Endocrinol 2008 6 50 10.1186/1477-7827-6-50 18990246 (Pubitemid 352722642)
39. The effects of inflammatory cytokines on steroidogenic acute regulatory protein expression in macrophages. Ma Y, Ren S, Pandak WM, Li X, Ning Y, Lu C, Zhao F, Yin L, Inflamm Res 2007 56 495 501 10.1007/s00011-007-6133-3 18210233
40. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. Cui Y, Miyoshi K, Claudio E, Siebenlist UK, Gonzalez FJ, Flaws J, Wagner KU, Hennighausen L, J Biol Chem 2002 277 17830 17835 10.1074/jbc.M200186200 11884400 (Pubitemid 34967591)
41. Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells. Chen Q, Sun X, Chen J, Cheng L, Wang J, Wang Y, Sun Z, Reprod Biol Endocrinol 2009 7 147 10.1186/1477-7827-7-147 20003221
42. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B, Wang LY, Yang SY, Zhang SH, Clin Endocrinol (Oxf) 2011 74 332 339 10.1111/j.1365-2265.2010.03917.x
43. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. Aroda VR, Ciaraldi TP, Burke P, Mudaliar S, Clopton P, Phillips S, Chang RJ, Henry RR, J Clin Endocrinol Metab 2009 94 469 476 10.1210/jc.2008-1133 18984667
44. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Brettenthaler N, De Geyter C, Huber PR, Keller U, J Clin Endocrinol Metab 2004 89 3835 3840 10.1210/jc.2003-031737 15292314 (Pubitemid 39071481)
45. Pioglitazone treatment decreases follicular fluid levels of tumor necrosis factor-alpha and interleukin-6 in patients with polycystic ovary syndrome. Kim CH, Ahn JW, You RM, Kim SH, Chae HD, Kang BM, Clin Exp Reprod Med 2011 38 98 102 10.5653/cerm.2011.38.2.98 22384426
46. Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells. Ohama Y, Harada T, Iwabe T, Taniguchi F, Takenaka Y, Terakawa N, Fertil Steril 2008 89 311 317 10.1016/j.fertnstert.2007.03.061 17555752 (Pubitemid 351215416)
47. Review: peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. Sharma AM, Staels B, J Clin Endocrinol Metab 2007 92 386 395 17148564